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a b s t r a c t
Substantial progress in cancer therapy increasingly allows higher cure rates, and even
advanced disease can be stabilized, allowing improved survival with quality of life for
months to years, meaning comorbid diseases are a growing determinant of outcome.
Cardiovascular events substantially contribute to long-term morbidity and mortality in
people living with or surviving cancer. In recognition of this, the subspecialty of cardio-
oncology has emerged, and aims to promote cardiovascular heath, whilst facilitating the
most effective cancer therapy. This review describes the concept of cardio-oncology, and
illustrates the role played by a specialist team in improving outcomes, using heart failure
secondary to breast cancer treatment as an example. We aim to highlight pivotal original
research and comprehensive summaries of the most relevant topics, providing an overview
for cardiologists and oncologists about this increasingly important medical problem.
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journal homepage: www.elsevier.com/locate/ihjIn recent decades, remarkable progress in the detection and
management of many common cancers has translated to
substantial improvements in disease-free and overall surviv-
al.1,2 Even in patients with noncurable cancer, contemporary
therapies can often achieve medium-term and sometimes
long-term disease control, requiring management strategies
more akin to many other chronic diseases. Similarly,
impressive reductions in cardiovascular mortality during
this period mean that an increasing proportion of the
population live with chronic cardiovascular diseases.3 Un-
surprisingly, these secular trends have also resulted in a
growing population of people with coexisting cancer and
cardiovascular disease, leading to challenging management
decisions that cross the boundaries of traditional medical
specialties. In particular, some recently introduced cancer* Corresponding author.
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article under the CC BY-NC-ND license (http://creativecommons.org/ltherapies achieve improved cancer outcomes, but with
greater cardiovascular toxicity, and so require careful case-
by-case consideration. In response to these concerns, the
subspecialty of cardio-oncology has developed. This review
not only describes the role of the cardio-oncologist, using the
prevention and management of heart failure in the setting of
breast cancer as a paradigm, but also discusses the back-
ground and breadth of this evolving discipline.
1. Cardiovascular risk in people with cancer
When managing cardiovascular disease in people with cancer,
it is important to consider the shared origins and potential
interactions of these diseases. Major cardiovascular risk, a division of Reed Elsevier India, Pvt. Ltd. This is an open access
icenses/by-nc-nd/4.0/).
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 7 7 – s 8 5S78factors, such as increasing age, cigarette smoking, and obesity,
are also unequivocally associated with the development of
many common cancers.4 Therefore, by the time cancer is
detected, many patients already have established or subclini-
cal cardiovascular disease, and conversely, increasing cardio-
vascular disease survivorship means more people survive to
develop cancer. For example, it has been shown that prior to
the onset of cancer treatment, patients with colorectal cancer
have reduced peak oxygen uptake during exercise, reduced
heart rate variability, and reduced left ventricular ejection
fraction, versus matched controls.5 It is also conceivable that
cancer per se exacerbates cardiovascular disease, perhaps by
creating a systemic proinﬂammatory state. Supporting this
assertion, recently published data from a heterogeneous
treatment naïve cancer cohort show that the concentrations
of many established cardiovascular and inﬂammatory bio-
markers rise with advancing cancer stage.6 It is therefore
unsurprising that if a period of cancer therapy successfully
achieves disease remission, future cardiovascular events may
represent a substantial risk to ongoing survival and quality of
life. For example, cardiovascular mortality is reported to
become the principal cause of death 10 years after the
diagnosis of breast cancer.7 Importantly, in many countries,
more than 75% of women survive 10 years after a diagnosis of
breast cancer, emphasizing the importance of cardiovascular
disease prevention in improving their overall survival.
2. The concept of cardio-oncology
The discovery and application of anthracycline chemotherapy
in the 1970s was perhaps the ﬁrst event to foster partnership
between oncologists and cardiologists, after it was recognized
that these agents were associated with the development of
heart failure.8 Since then, a number of other factors, including
improving cancer survival and the cardiovascular toxicity of
radiotherapy and molecular targeted therapies (e.g. Trastu-
zumab, Bevacizumab, and tyrosine kinase inhibitors), have
prompted the need for increasingly formal cardiology–oncol-
ogy collaborations. The concept of cardio-oncology as a
subspecialty in its own rite has been embraced more rapidly
in some healthcare systems than others, but remains a
nascent discipline in the context of clinical cardiology or
oncology.9 The overarching aims of the cardio-oncologist are
to facilitate effective cancer therapy, whilst minimizing
cardiovascular sequelae, and this requires careful consider-
ation of the risks and beneﬁts of the treatment strategies being
considered. Most often, continuing optimal cancer therapy is
appropriate, whilst minimizing, and ideally preventing,
interruption of cancer therapy unless it is likely that continu-
ing will result in a net adverse outcome. Even in these
circumstances, it is often possible to rapidly optimize a
patient's cardiovascular status, such that cancer therapy
can safely recommence with appropriate monitoring.
These potentially life-changing decisions require clear
communication between a large multidisciplinary team
including cardiologists, oncologists, the patient, and their
family, and often require periodic reconsideration during a
course of therapy. The additional complexities of considering
optimal cancer care can make decision-making challenging,emphasizing the importance of understanding the mecha-
nisms of toxicity, and beneﬁts of cancer therapy, which
requires clear communication with the oncology team.
Furthermore, many decisions must be based on limited
evidence, and in the context of rapidly evolving cancer
therapeutics, so experience and expert opinion become
increasingly important. These challenges make cardio-oncol-
ogy an exciting and dynamic ﬁeld, with major opportunities to
improve clinical outcomes, both through organized systems of
current clinical care and research programs. In spite of the
complexity of individual patient circumstances, the majority
of referrals to a cardio-oncology service conform a relatively
small number of broad themes (Fig. 1). It is beyond the scope of
this review to discuss each comprehensively, so we use the
examples of heart failure prevention and management in the
setting of breast cancer for the purposes of illustration.
Importantly, the general principles we discuss are transferable
to many other scenarios encountered by cardio-oncology
teams.
3. Mechanisms of cardiac toxicity
Breast cancer is often managed with an array of highly
effective, yet potentially cardiotoxic therapies. Our under-
standing of the mechanisms underlying this toxicity remains
incomplete, although emerging studies have provided poten-
tially important insights. Anthracycline toxicity has for many
years been attributed to the myocardial oxidative stress, and
recent work from Ichikawa et al. suggests this may be
secondary to mitochondrial iron overload.10 Furthermore,
they showed that Dexrazoxane, which may mitigate anthra-
cycline cardiotoxicity in humans, is able to reduce the
accumulation of iron within mitochondria. Zhang et al. have
proposed anthracycline-mediated inhibition of myocardial
Topoisomerase-2b as the causal mechanism, leading them to
hypothesize that Topoisomerase-2a speciﬁc agents may target
cancer with less cardiac toxicity.11 It is also possible that
Dexrazoxane reduces anthracycline toxicity by interfering
with their binding to Topoisomerases.12 It is likely that toxicity
is multifactorial, with both of these mechanisms and others
potentially playing a role. These studies provide hope for a
mechanistic basis for strategies to reduce the cardiovascular
effects of these crucial chemotherapeutic agents.
Trastuzumab (or Herceptin) is another important thera-
peutic agent in patients with HER2 (human epidermal growth
factor receptor-2, or ErbB2) overexpressing breast cancer. This
monoclonal antibody binds to ErbB2, interfering with its
growth and survival promoting effects in tumor cells, although
when clinical trials showed an increased risk of heart failure, it
became apparent that ErbB2 was also important in the
myocardium. Indeed, we now recognize that cardiac epider-
mal growth factor receptor signaling plays an important role in
the survival response to pathological stressors,13 although this
insight has not yet resulted in the development of cancer
therapies with less cardiac toxicity. It is also important to
remember that the heart and wider vasculature are sensitive
to the DNA-damaging effects of radiotherapy used in many
breast cancer treatment regimens14; nontumor tissue dose
reductions represent the best means of mitigating this toxicity.
Fig. 1 – Common referrals to a cardio-oncology service. Illustration of the broad themes of referral to a cardio-oncology service.
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The diverse mechanisms of chemotherapy-associated cardiac
toxicity have been linked with differing clinical presentation
and response to treatment, resulting in attempts to formally
classify different forms. Historically, type 1 cardiotoxicity
refers to a persistent and irreversible myocardial insult, as is
commonly implicated in people receiving anthracyclines,
whilst type 2 denotes a transient reversible deterioration in
cardiac function, as has been suggested in Trastuzumab
recipients. However, as with many clinical classiﬁcations,
these are somewhat false distinctions, and many exceptions to
these patterns are observed. For example, recent observational
data suggest that normalization of anthracycline-associated
left ventricular systolic dysfunction can occur after commenc-
ing appropriate heart failure therapy.15 Moreover, with the
advent of more sensitive imaging techniques, it is now clear
that many cases of Trastuzumab-related left ventricular
systolic dysfunction are associated with the development of
myocardial scarring.16
Although it is difﬁcult to quantify an individual patient's
risk of anthracycline-related cardiac toxicity, there is a clear
association with cumulative lifetime dose.8 Importantly, there
is no threshold dose below which these risks are absent, so
potential risks and beneﬁts must be carefully considered when
planning chemotherapy. Recent data from a large heteroge-
neous cancer cohort (51% breast cancer) have shown that
routine regimens (mean doxorubicin equivalent cumulative
dose <360 mg/kg) are associated with cardiotoxicity in almost
10% of patients.15 Whilst this is more common than suggested
by early publications on anthracycline cardiotoxicity,8 this to
some extent reﬂects the routine use of serial cardiac imaging,
instead of clinical evidence of heart failure, to deﬁne toxicity.
Cardinale et al. also found larger cumulative anthracycline
dose, lower baseline left ventricular ejection fraction (LVEF),
and some cardiovascular risk factors (e.g. diabetes), to be
associated with risk of cardiotoxicity.15 Their work alsochallenged the dogma, showing that most anthracycline
toxicity is detectable within one year of completing chemo-
therapy, and that complete (11%) or partial (71%) improvement
in left ventricular function commonly occurs after commenc-
ing heart failure therapy.
Whilst data describing the incidence of Trastuzumab-
associated cardiac toxicity are also conﬂicting, it is widely
accepted that concurrent use with anthracyclines substantial-
ly increases cardiotoxicity. For example, in the initial trails of
concurrent therapy in women with metastatic breast cancer,
the incidence of NYHA class 3 or 4 heart failure was high at 16%
versus 3%.17 However, it is important to note that in spite of
this adverse interaction, the addition of Trastuzumab
remained associated with markedly improved overall survival.
Based upon these data, subsequent trials in women with
nonmetastatic breast cancer applied agents sequentially, with
an interval between anthracycline and Trastuzumab, includ-
ing an assessment of LVEF. For example, the HERA trial, which
mandated 3 months separation between anthracycline and
Trastuzumab, demonstrated a markedly lower incidence of
clinical heart failure (0.6% vs. 0% in placebo arm) or decline in
LVEF (3% vs. 0.5% in placebo arm), supporting this more
cautious strategy.18 However, patients recruited to clinical
trials are prescreened to exclude cardiovascular disease, and
are at lower risk of adverse outcomes than are patients
currently receiving chemotherapy; so caution should be
applied in extrapolating such data to routine practice.
Moreover, clinical trials tend to report adverse cardiovascular
events using somewhat crude, arbitrary, and overlapping
criteria that require the presence of major symptoms or
declines in LVEF to be deemed high-grade toxicity. For
example, the Common Terminology Criteria for Adverse
Events deem major (grade 3/5) heart failure to manifest with
at least NYHA class 3 breathlessness.19 However, a similar
toxicity grading would be applied using the left ventricular
systolic dysfunction criterion if a symptomatic drop in LVEF
occurred. This inconsistency is a key factor in reconciling
differences between clinical trials, and between trials versus
i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) s 7 7 – s 8 5S80observational studies systematically recording cardiac imag-
ing and/or biomarkers.
Radiotherapy used in the setting of breast (and other
thoracic) cancer does not tend to adversely effect left
ventricular systolic function in the acute phase, but may
promote atherogenesis and valvular heart disease in the long-
term.14 A meta-analysis of radiotherapy trials in this setting
has supported an adverse cardiovascular risk over 15 years of
follow-up, although much of the data described somewhat
dated radiotherapy strategies.20 Indeed, other studies have
failed to demonstrate this association,21 although the most
recently published large cohort follow-up data continue to
show a dose-dependent relationship between radiotherapy
and increased cardiovascular risk.22
5. Assessing the risk of cardiac toxicity
The rationale of cardiotoxicity prevention is usefully contex-
tualized by the American Heart Association heart failure
staging system,23 which emphasizes that symptomatic ven-
tricular dysfunction is often an avoidable late stage in a
chronic process (Fig. 2). As discussed earlier, patients with
cancer frequently have other important risk factors for the
development of heart failure, such as diabetes or hyperten-
sion, and these will synergize with cancer treatment-related
factors to increase risk. Therefore, the ﬁrst step in preventing
heart failure should be a careful clinical assessment of
modiﬁable and nonmodiﬁable risk factors, during a compre-
hensive clinical assessment. During any baseline assessment,
it is also important to clarify the cancer therapy that is planned
by the oncology team. Based on the earlier discussion of long-
term anthracycline- and radiotherapy-associated toxicity, it is
also important to carefully explore prior cancer therapy. Next,
it is essential to document cardiovascular risk factors and also
consider prior or ongoing manifestations of cardiovascular
disease, such as angina, which may suggest progression
beyond stage A of the heart failure classiﬁcation. A standard
cardiovascular examination should deﬁne blood pressure,
features of valvular heart disease, and signs of heart failure.
Routine investigations should be deﬁned by the potential risks
of the cancer therapy planned, and in the case of standardFig. 2 – Heart failure staging in the context of cardio-oncology. T
provides a useful framework to consider the opportunities to de
GLS – global longitudinal strain; LVEF – left ventricular ejection breast cancer therapy, blood tests (full blood count, renal
function and electrolytes, liver function, glucose), a 12-lead
ECG, and transthoracic echocardiogram are warranted. This
baseline assessment provides a valuable opportunity to
modify risk factors for heart failure when possible (Stage A),
prevent the progression of asymptomatic structural heart
disease (Stage B), and identify overt heart failure (Stage C).
Patients in stage B/C, should commence neurohormonal
blockade with an angiotensin-converting enzyme inhibitor
and beta-blocker (discussed in detail later), then undergo
reassessment to consider the risks and beneﬁts of potentially
suitable cancer therapies. This may result in selection of
regimens not requiring the use of anthracyclines or Trastu-
zumab, but these are complex decisions requiring multidisci-
plinary consideration.
6. Detection of early cardiac toxicity
Monitoring for the development of early cardiac toxicity is a
crucial component of heart failure prevention, and must be
conducted on an individual patient basis, with more frequent
monitoring being advisable for those at greatest perceived risk.
In the context of patients with breast cancer receiving
anthracyclines followed by Trastuzumab, elective reassess-
ment is usually performed after anthracyclines, unless there is
clinical suspicion of cardiovascular toxicity in the interim.
Serial clinical assessment, in conjunction with cardiac imag-
ing, and possibly circulating biomarkers, forms the basis of
most guidelines, although it must be emphasized that the
evidence base for these is limited and evolving. Moreover, we
currently lack data from randomized-controlled trials of
approaches to detect cardiac toxicity, and as discussed earlier,
inconsistencies in outcome measures of heart failure or
altered cardiac function hamper the comparison of observa-
tional studies.
When using the information generated from serial cardiac
imaging, it is important to be aware of the limitations of this
approach, which could lead to inappropriate cessation of
chemotherapy, or late detection of heart failure, if overlooked.
Two crucial concepts to consider are: (1) the test–retest
variability of measures of cardiac function; and, (2) thehe American Heart Association Heart Failure staging system
tect and prevent chemotherapy-associated cardiotoxicity.
fraction.
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early cardiac dysfunction, and the risk of heart failure. Test–
retest variability, which encompasses biological variability
(independent of chemotherapy) and assay variability, effec-
tively represents the between-test variation that would be
found in a control population. As this variability increases, a
serial imaging approach is less able to conﬁdently suggest that
a modest change in cardiac function is genuine. For example,
Simpson's biplane assessment of LVEF using noncontrast 2-
dimensional transthoracic echocardiography (2D-TTE) has an
absolute test–retest variation of at least 10%.24 In other words,
a drop in LVEF from 60% to 50% may be within the margin of
variation, which calls in to question the value of this approach
when some clinical practice guidelines recommend changes in
chemotherapy if LVEF drops by 10%. The next important
consideration is whether such a change in LVEF represents an
early stage of cardiac toxicity, amenable to intervention, or a
late manifestation of potentially irreversible damage. As
imaging approaches have evolved, we now appreciate that
the latter description is most accurate; indeed, people at-risk
of heart failure, but with normal LVEF, frequently have
detectable LV dysfunction using more sensitive approaches,
such as strain imaging.25 The challenge of such increased
sensitivity though is reduced speciﬁcity, and whether to
intervene with cardioprotective therapies in all cases. Howev-
er, it is critical that no changes to potentially life-saving
chemotherapy are made based on these changes in very
sensitive markers of cardiotoxicity. There is no simple solution
to these challenges, but a cardio-oncology team should always
be aware of them when monitoring toxicity.
Historically, multiple-gated acquisition (MUGA) radionu-
clide imaging formed the mainstay of cardiac monitoring in
patients receiving potentially cardiotoxic therapy. Whilst it
can reproducibly measure LVEF than 2D-TTE,26 and reductions
during chemotherapy have been associated with adverse
outcome,27,28 it may result in signiﬁcant cumulative radiation
exposure (10 mSv per study), limiting repeated imaging.
Hence, as ultrasound technology has evolved, 2D-TTE has
become routinely adopted in many centers, but as discussed
above, this technique is much less reproducible, even in the
hands of highly experienced operators.24 Whilst preche-
motherapy LVEF measured by 2D-TTE has been linked with
poor prognosis,29 fewer data exist regarding the prognostic
relevance of changes in 2D-TTE LVEF.30 It is not clear that
routine use of echo-contrast agents improves the reproduc-
ibility of LVEF measures,24 but may help in selected cases.
However, it appears that 3-dimensional transthoracic echo
(3D-TTE) may substantially improve test–retest variability,
meaning that changes in LVEF approaching 5% can be
detected.24 However, given concerns that detectable changes
in LVEF may miss early cardiotoxicity, more recent studies
have focused alternate indices of myocardial function. For
example, one small study has used tissue Doppler imaging
(TDI) to document Trastuzumab-associated reductions in peak
mitral annular systolic velocity, which were detectable before
LVEF declined.16 Speckle-tracking echo-derived global longi-
tudinal strain (GLS) has demonstrated particular promise in
detecting early and prognostically relevant cardiotoxicity in a
recent systematic review.31 This suggested a 10–15% relative
decline in GLS was the optimal cut-off, associated withsensitivity and speciﬁcity of 80% to detect variously deﬁned
cardiotoxicity. However, these newer techniques are yet to be
tested as part of formal pathways of care, so it remains unclear
that their use can improve outcome via early institution of
preventative measures. Cardiac magnetic resonance imaging
also offers a highly reproducible means of assessing LVEF, in
addition to deﬁning other aspects of toxicity (e.g. myocardial
scarring), although availability, cost, and comfort generally
limits its use as a routine monitoring tool.16,25
The technical and logistical limitations of cardiac imaging
modalities have also prompted the search for effective
biomarkers of early cardiac toxicity. Over a decade ago,
Cardinale et al. published a large observational study of a
mixed cancer cohort receiving high-dose chemotherapy,
deﬁning the value of Troponin I (TnI) measured 5 times in
the 72 h after chemotherapy, and once more a month later.32
They found that TnI ≥0.08 ng/ml during the early phase (using
the highest of the 5 recorded values), or at one month, was
associated with deterioration in LVEF during one-year follow-
up. Moreover, those with TnI ≥0.08 ng/ml on both occasions
(63/703 patients) experienced very high risk of heart failure
(44%), compared with those with only early TnI elevation (12%)
or no TnI elevation (0.2%). However, these impressive results
are challenging to apply in routine cancer care, due to the
requirement of serial blood sampling during the 3 days after
chemotherapy. More recently, the same authors have deﬁned
the impact of TnI ≥0.08 ng/ml in women with breast cancer
receiving Trastuzumab (after chemotherapy with or without
anthracyclines). Blood sampling was performed before and
after every cycle of Trastuzumab, with treating clinicians being
blinded to the result.33 Any elevation of TnI ≥0.08 ng/ml
(occurring in 14%) was associated with a 17.6-fold increased
risk of cardiac toxicity (decline in LVEF >10% from baseline,
associated with LVEF decline to <50%) even after accounting
for potential confounding factors. Most elevations of TnI were
detectable by completion of the second cycle of Trastuzumab.
Many other studies suggest that TnI elevation (above various
thresholds) in women receiving chemotherapy for breast
cancer is associated with future cardiotoxicity,34,35 although
some smaller studies have failed to recapitulate this.36
Although some small studies have suggested that natriuretic
peptides may also aid the prediction of early cardiotoxicity in
women undergoing chemotherapy for breast cancer,37 a strong
evidence base for this is currently lacking.
Other studies have introduced the concept of measuring
multiple biomarkers in an attempt to reﬁne prognostication.
As discussed earlier, patients with cancer about to commence
treatment exhibit higher concentrations of multiple cardio-
vascular biomarkers than healthy controls.6 In women with
breast cancer, many of these biomarkers rise during both
anthracycline and Trastuzumab therapies,38 and it is possible
that the addition of myeloperoxidase to TnI may provide
incremental prognostic data,35 although validation is awaited.
Some groups have also asked whether biomarkers can
complement cardiac imaging to deﬁne early cardiotoxicity.
In 42 women receiving Trastuzumab for HER2+ breast cancer,
Fallah-Rad et al. noted no change in Troponin T, high-
sensitivity C-reactive protein, or brain natriuretic peptide,
measured at 3 monthly intervals for one year.16 However,
even at 3 months, they noted signiﬁcant declines in echo
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offered 92% negative predictive value for future cardiotoxicity.
Sawaya et al. noted somewhat different ﬁndings in 81 women
with breast cancer, assessed in the interval between anthra-
cycline and Trastuzumab therapies.34 From a panel of
advanced echo parameters and biomarkers, they found that
peak systolic GLS <19% and ultrasensitive TnI <30 pg/ml
predicted absence of cardiotoxicity. However, in multivariate
analysis, only GLS remained signiﬁcantly associated with
cardiotoxicity. Before meaningful conclusions can be reached
regarding the value of imaging and biomarkers in this setting,
randomized controlled trials with large sample sizes must be
conducted.
7. Preventative therapies
The ﬁrst step in preventing cardiotoxicity is to be aware of the
baseline cardiovascular risk in an individual patient, along
with the factors that contribute to this risk; this is an iterative
process, which should continue throughout treatment. For
patients with nonchemotherapy-related risk factors, such as
hypertension or smoking, these should be optimized, although
this requires an individualized approach. This recommenda-
tion follows expert consensus, rather than clinical trial derived
evidence, but is unlikely to do harm, provided that cancer
therapy is not delayed. Chemotherapy-related factors are also
important in determining risk of toxicity, and the cardio-
oncology team must weigh the risks of toxicity against the
beneﬁts of effective cancer control for all potentially suitable
regimens. It may also be possible to reduce the risk of
anthracycline-containing regimens by modifying their admin-
istration and using adjunctive therapies. For example, a recent
Cochrane Collaboration systematic review and meta-analysis
suggested that anthracycline cardiotoxicity is reduced by
using longer infusion times, although this strategy does
present logistical challenges.39
The United States Federal Drug Administration has also
approved the use of adjunctive Dexrazoxane to reduce the
risk of anthracycline cardiotoxicity in women with breast
cancer receiving high-dose chemotherapy.40 Whilst the
mechanism of this agent's beneﬁt remains debated, there
is reasonable evidence for its prevention of cardiotoxicity.41
Although concerns have been raised this may come at the
cost of reduced anticancer efﬁcacy, long-term follow-up of
children receiving this agent has suggested no survival
disadvantage or increased risk of adverse cancer outcomes.42
Emerging evidence suggests that in patients with hemato-
logic malignancy and normal LVEF, as a result of receiving
intensive chemotherapy, prophylactic use of Enalapril and
Carvedilol can substantially reduce the development of heart
failure or declining LVEF.43 This is also supported by meta-
analysis of smaller clinical trials in patients with various
cancers,41 along with a potential beneﬁt of statins; yet,
further validation is needed before this could be considered
as routine management.
For patients who develop stage B or C heart failure, a
different approach is clearly warranted. There is good
evidence to suggest that many of these people will respond
well to the standard neurohormonal blockade (with anangiotensin-converting enzyme inhibitor and beta-blocker)
that would be offered to any other patient without cancer in
these circumstances.15,44 Whilst these data are only from
observational studies, and cannot deﬁne the prognostic
beneﬁt of this intervention, it is unlikely that randomized
controlled trials of neurohormonal blockade in this secondary
prevention setting would be deemed ethically justiﬁable.
Potentially cardiotoxic chemotherapy is often halted in
patients who develop signiﬁcant LV dysfunction, although
in those patients where LV function recovers to normal, it can
be appropriate to reinitiate some therapies (e.g. Trastuzumab)
with close monitoring. Importantly, recent data also indicate
that many patients with chemotherapy-associated heart
failure receive suboptimal cardiovascular care,45 indicating
the scope of a cardio-oncology team to improve cardiovascular
and cancer outcomes. It is not possible, or desirable, to be
dogmatic about the circumstances where chemotherapy
should stop or recommence, as decisions must carefully
balance the risks of avoiding cancer treatment against further
cardiac toxicity. However, whilst individualized care is
important, in many cases, the opportunities to detect and
prevent cardiotoxicity in patients receiving cancer therapy are
broadly similar (Fig. 3). Some national guidelines exist to
support such decision making in common scenarios, such as
Trastuzumab cardiotoxicity,46 but it must be reemphasized
that cardio-oncology teams should formulate bespoke plans in
conjunction with patients.
8. Other cardio-oncology considerations
Although this review has deliberately focused on heart failure
as a manifestation of cardiovascular toxicity of chemotherapy,
it is important to brieﬂy highlight other cardiovascular
toxicities. Firstly, hypertension is a common problem encoun-
tered by patients receiving 'targeted therapy' with tyrosine
kinase inhibitors (TKIs), or direct antagonists of growth factors,
such as vascular endothelial growth factor.47 This hyperten-
sion can directly contribute to cardiac failure and other
cardiovascular sequalae, and may also act as an indirect
indicator of on-target toxicity (within the tumor and other
tissue, such as the myocardium). Patients receiving these
agents should be advised to purchase a home blood pressure
monitor if possible, and keep a blood pressure diary. If not
logistically possible, then they should undergo regular blood
pressure monitoring at the clinic, and commence standard
antihypertensive therapy if their blood pressure consistently
exceeds 140/90 mmHg.48 Inadequate blood pressure control
can theoretically be a justiﬁcation to change cancer therapy,
where risks of ongoing toxicity outweigh anticipated beneﬁts;
however, in most cases, this side effect can be well controlled
over many years of therapy, and if the cancer is responding,
then every effort must be made to control blood pressure. As
growing numbers of patients are receiving long-term TKI
therapy, it is increasingly clear that we will have to consider
broader vascular and metabolic effects of these agents, which
are often agent speciﬁc, and not predicted from early clinical
trials.48 For example, arterial and venous thrombosis, pulmo-
nary hypertension, diabetes, and cardiac arrhythmia have all
been attributed to different targeted molecular therapies.
Fig. 3 – Schema of cardiotoxicity detection and prevention. The general approach to detecting and managing chemotherapy-
associated cardiotoxicity is provided in the context of the American Heart Association Heart Failure staging system. GLS –
global longitudinal strain; LVEF – left ventricular ejection fraction; TDI – tissue Doppler imaging.
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prevalent problem in cancer patients, which poses dilemmas
regarding choice of anticoagulant, and how to deﬁne the risks/
beneﬁts of anticoagulation in individuals.49
9. Concluding remarks
This brief review has highlighted the increasing importance of
cardiovascular disease management in people with cancer, and
emphasized the important role of the cardio-oncology team in
this complex and evolving process. Developing a cardio-
oncology service is not a simple objective,50 and requires careful
coordination with potential stakeholders and funders, but
offers an important opportunity to improve clinical outcomes,
and conduct valuable research. Whilst many large cardiology
departments still do not have a dedicated cardio-oncology
service, this is likely to become increasingly relevant subspeci-
ality, with a pivotal role in increasing the longer-term survival
and well being of many cancer sufferers.
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